Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat

Abstract Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a dismal prognosis. The average life expectancy of untreated patients with IPF is only 3 to 4 years. Decline in forced vital capacity (FVC) in patients with IPF appears to be almost linear, with patients with well-preserved F...

Full description

Bibliographic Details
Main Authors: Toby M. Maher, Mary E. Strek
Format: Article
Language:English
Published: BMC 2019-09-01
Series:Respiratory Research
Subjects:
Nintedanib
Pirfenidone
Interstitial lung disease
Therapeutics
Treatment
Mortality
Online Access:http://link.springer.com/article/10.1186/s12931-019-1161-4

Internet

http://link.springer.com/article/10.1186/s12931-019-1161-4

Similar Items